IDEXX Laboratories (IDXX) Projected to Announce Quarterly Earnings on Tuesday

IDEXX Laboratories (NASDAQ:IDXX) is anticipated to announce its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect the company to post earnings of $3.94 per share and revenue of $1.2002 billion for the quarter. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 8:30 AM ET.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The company had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.12 billion. During the same period in the previous year, the firm earned $2.91 earnings per share. IDEXX Laboratories’s revenue for the quarter was up 14.3% compared to the same quarter last year. On average, analysts expect IDEXX Laboratories to post $15 EPS for the current fiscal year and $17 EPS for the next fiscal year.

IDEXX Laboratories Trading Up 2.2%

NASDAQ:IDXX opened at $556.20 on Tuesday. The stock has a fifty day simple moving average of $556.48 and a 200 day simple moving average of $593.74. The firm has a market capitalization of $43.87 billion, a price-to-earnings ratio of 40.96, a price-to-earnings-growth ratio of 2.98 and a beta of 1.55. IDEXX Laboratories has a 1-year low of $518.55 and a 1-year high of $769.98. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19.

Wall Street Analyst Weigh In

A number of research firms have commented on IDXX. UBS Group reduced their price objective on shares of IDEXX Laboratories from $640.00 to $620.00 and set a “neutral” rating for the company in a research note on Monday. Stifel Nicolaus reduced their target price on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a report on Tuesday, March 31st. Wall Street Zen lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Weiss Ratings cut IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Tuesday, July 14th. Finally, Citigroup began coverage on IDEXX Laboratories in a report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price target on the stock. Six research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, IDEXX Laboratories presently has an average rating of “Moderate Buy” and an average target price of $749.00.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Virtus Advisers LLC acquired a new stake in shares of IDEXX Laboratories in the 3rd quarter valued at $26,000. WealthCollab LLC bought a new position in IDEXX Laboratories during the second quarter valued at about $30,000. Caitong International Asset Management Co. Ltd bought a new position in IDEXX Laboratories during the third quarter valued at about $36,000. Johnson Financial Group Inc. lifted its position in shares of IDEXX Laboratories by 1,475.0% in the third quarter. Johnson Financial Group Inc. now owns 63 shares of the company’s stock worth $40,000 after buying an additional 59 shares during the last quarter. Finally, Kemnay Advisory Services Inc. acquired a new stake in shares of IDEXX Laboratories in the fourth quarter worth about $54,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.